araag2/HINT huggingface dataset:
Clinical trial NCT01006291 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, insulin degludec, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

          -  Current treatment: oral anti-diabetic drug(s) (OAD(s)) alone, basal insulin alone or
             the combination of OAD(s) and basal insulin. Allowed OADs are: Metformin, insulin
             secretagogues (sulphonylureas (SU) or glinides), pioglitazone with unchanged dosing
             for at least 3 months prior to Visit 1

          -  HbA1c: OADs only users 7.0-11.0 % (both inclusive), basal insulin with/without OADs
             users 7.0-10.0% (both inclusive) by central laboratory analysis

          -  Body Mass Index (BMI) below or equal to 40.0 kg/m^2

        Exclusion Criteria:

          -  Cancer and medical history of cancer hereof

          -  Use within the last 3 months prior to Visit 1 of: glucagon-like peptide-1(GLP-1)
             receptor agonist (exenatide, liraglutide), rosiglitazone, dipeptidyl peptidase IV
             (DPP-IV) inhibitors, alpha-glucosidase-inhibitors

          -  Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke;
             decompensated heart failure New York Heart Association (NYHA) class III or IV;
             myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty

          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least
             180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
             contraceptive measures according to local requirements

          -  Cancer and medical history of cancer hereof (except basal cell skin cancer and
             squamous cell skin cancer)
Clinical trial NCT01017874 (phase 3, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, cisplatin, gefitinib, gefitinib
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histological diagnosis of NSCLC with locally advanced or metastatic disease that is of
             non-squamous histology.

          -  Participants must be "light ex-smokers" or "never-smokers".

               -  "Light ex-smokers" defined as having ceased smoking for greater than or equal to
                  5 years and not to have exceeded 10 pack-years.

               -  "Never-smokers" are defined as having smoked <100 cigarettes or equivalent during
                  his/her lifetime.

          -  Participants must be of East Asian ethnicity.

          -  No prior systemic therapy for lung cancer.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

        Exclusion Criteria:

          -  Presence of clinically significant (by physical exam) third-space fluid collections,
             for example, ascites or pleural effusions that cannot be controlled by drainage or
             other procedures prior to study entry.

          -  Any evidence of clinically active interstitial lung disease. Asymptomatic participants
             with chronic, stable, radiographic changes are eligible.

          -  Participants whose Epidermal Growth Factor Receptor (EGFR) mutation status is known
             prior to study entry will be excluded. Participants in which EGFR mutation testing has
             not been performed, or whose EGFR mutation status is unknown or inconclusive at study
             entry are eligible.
Clinical trial NCT01431274 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: tiotropium + olodaterol, tiotropium, olodaterol, tiotropium, tiotropium + olodaterol
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion criteria:

          1. Diagnosis of chronic obstructive pulmonary disease.

          2. Relatively stable airway obstruction with post FEV1< 80% predicted normal and post
             FEV1/FVC <70%.

          3. Male or female patients, 40 years of age or older.

          4. Smoking history of more than 10 pack years.

        Exclusion criteria:

          1. Significant disease other than COPD

          2. Clinically relevant abnormal lab values.

          3. History of asthma.

          4. Diagnosis of thyrotoxicosis

          5. Diagnosis of paroxysmal tachycardia

          6. History of myocardial infarction within 1 year of screening visit

          7. Unstable or life-threatening cardiac arrhythmia.

          8. Hospitalization for heart failure within the past year.

          9. Known active tuberculosis.

         10. Malignancy for which patient has undergone resection, radiation therapy or
             chemotherapy within last five years

         11. History of life-threatening pulmonary obstruction.

         12. History of cystic fibrosis.

         13. Clinically evident bronchiectasis.

         14. History of significant alcohol or drug abuse.

         15. Thoracotomy with pulmonary resection

         16. Oral ß-adrenergics.

         17. Oral corticosteroid medication at unstable doses

         18. Regular use of daytime oxygen therapy for more than one hour per day

         19. Pulmonary rehabilitation program in the six weeks prior to the screening visit

         20. Investigational drug within one month or six half lives (whichever is greater) prior
             to screening visit

         21. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA

         22. Pregnant or nursing women.

         23. Women of childbearing potential not using a highly effective method of birth control

         24. Patients who are unable to comply with pulmonary medication restrictions
Clinical trial NCT00515619 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: lacosamide
SMILES: COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosis of Epilepsy

          -  completion of double blind trial

        Exclusion Criteria:

          -  taking other investigational drug than Lacosamide

          -  meeting withdrawal criteria from double blind trial
Clinical trial NCT00265811 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: folfox, cetuximab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage III adenocarcinoma of the colon

          -  Must have undergone curative resection (R0) within the past 28-56 days

               -  No radiotherapy prior to surgery

          -  carcinoembryonic antigen (CEA) ≤ 1.5 times upper limit of normal (ULN) after surgery

          -  No rectal cancer located within 15 cm from the anal verge by endoscopy or under the
             peritoneal reflection at surgery

          -  No metastatic spread at baseline assessment

          -  No prior or concurrent CNS disease by physical exam

        PATIENT CHARACTERISTICS:

        Performance status

          -  WHO 0-1

        Life expectancy

          -  At least 5 years

        Hematopoietic

          -  WBC ≥ 3,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL

        Hepatic

          -  Bilirubin ≤ 1.5 times ULN

          -  AST and ALT ≤ 2.5 times ULN

          -  Alkaline phosphatase ≤ 1.5 times ULN

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Cardiovascular

          -  No coronary artery disease

          -  No myocardial infarction within the past 12 months

          -  No high risk of uncontrolled arrhythmia

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No inflammatory bowel disease

          -  No other malignancy within the past 5 years except basal cell skin cancer or carcinoma
             in situ of the cervix

          -  No significant traumatic injury within the past 28 days

          -  No known hypersensitivity to any of the components of the study drugs

          -  No medical, geographical, sociological, psychological, or legal condition that would
             preclude study participation

          -  No peripheral neuropathy ≥ grade 1

          -  No other significant disease that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Chemotherapy

          -  No prior chemotherapy

        Radiotherapy

          -  See Disease Characteristics

          -  No prior abdominal or pelvic irradiation

        Surgery

          -  See Disease Characteristics

          -  Recovered from prior surgery

          -  More than 28 days since prior major surgical procedure or open biopsy

          -  No concurrent major surgical procedure
Clinical trial NCT01010061 (phase 3, status: completed)
Conditions: lymphocytic leukemia, chronic
ICD codes: C91.11, C91.12, C91.10
Drugs: obinutuzumab, rituximab, chlorambucil
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  Adults >/=18 years

          -  Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic
             Lymphoma (B-CLL)

          -  Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according
             to the National Cancer Institute (NCI) criteria

          -  Total Cumulative Illness Rating Scale (CIRS) > 6 and/or creatinine clearance < 70
             ml/min

        Exclusion Criteria:

          -  Prior CLL therapy

          -  Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's
             transformation)

          -  History of other malignancy unless the malignancy has been in remission without
             treatment for >/=2 years prior to enrolment, and except for carcinoma in situ of the
             cervix, basal or squamous cell skin cancer, surgically treated low-grade prostate
             cancer, or ductal carcinoma in situ (DCIS) of the breast treated with lymphectomy
             alone

          -  Positive hepatitis serology (HBV, HCV) or positive HIV or Human T Cell Leukemia Virus
             (HTLV) testing

          -  Patients with active infection requiring systemic treatment
Clinical trial NCT00689156 (phase 3, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: epirubicin, cyclophosphamide and docetaxel, docetaxel, cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Trial Population:

          1. Younger than 35, but at least 18 years of age

          2. Hormone receptor-negative tumor (ER- and PgR-negative) and 35 to 75 years of age.

          3. Hormone receptor-positive tumor, 35 to 59 years of age and presenting at least one of
             the following characteristics: spread to lymph nodes, tumor > 2 cm, degree of
             malignancy II-III or HER2-positive.

        Inclusion Criteria:

          1. Signed informed consent

          2. Histologically confirmed invasive breast carcinoma which has been micro-radical
             removed by breast preserving surgery or mastectomy according to DBCG's guideline

          3. TOP2A normal tumor (score of 0.8 - 2.0)

        Exclusion Criteria:

          1. Pregnancy or breast-feeding

          2. Earlier medical cancer treatment, including docetaxel, epirubicin or cyclophosphamide.

          3. Distant metastases or bilateral breast cancer (excluded after checking by means of
             chest radiography, bilateral mammography and normal blood samples as a minimum).

          4. Other active, malign disease in the latest 5 years, except for adequately treated and
             cured carcinoma in situ cervices uteri or non-melanoma skin cancer.

          5. Comorbidity score > 3 (patients with a score of 1-2 start at dose level -1).

          6. Treatment with a non-approved product or test product in the latest 30 days.

          7. Known severe hypersensitivity to docetaxel, epirubicin or cyclophosphamide or
             auxiliary agents in these products.
Clinical trial NCT00003647 (phase 3, status: completed)
Conditions: stage iv melanoma, stage iii melanoma, recurrent melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2
Drugs: allovectin-7, allovectin-7/dacarbazine, dacarbazine
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O, N1C=CN=C1
Eligibility criteria:

        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Histologically confirmed stage III or IV melanoma 1 or more metastatic tumors for
             which surgery is not deemed to be a curative option

          -  Dacarbazine is indicated as first line chemotherapy

          -  At least 1 measurable tumor at least 1 cm2 but no greater than 100 cm2

          -  No history of brain metastases

        --Prior/Concurrent Therapy--

          -  Biologic therapy: At least 4 weeks since prior biologic therapy

          -  Chemotherapy: See Disease Characteristics; No prior chemotherapy

          -  Endocrine therapy: No concurrent immunosuppressive drugs

          -  Radiotherapy: At least 4 weeks since prior radiotherapy

          -  Surgery: At least 2 weeks since prior major surgery

          -  Other: No other concurrent anticancer drug therapy or experimental therapy

        --Patient Characteristics--

          -  Age: 18 and over

          -  Performance status: Karnofsky 80-100%

          -  Life expectancy: At least 24 weeks

          -  Hematopoietic: WBC at least 3,000/mm3; Platelet count at least 100,000/mm3; Hemoglobin
             at least 9 g/dL

          -  Hepatic: Bilirubin no greater than 2.0 mg/dL; SGOT/SGPT less than 3 times upper limit
             of normal (ULN); PT/PTT normal; Albumin normal; LDH no greater than 2 times ULN

          -  Renal: Creatinine no greater than 2.0 mg/dL

          -  Cardiovascular: No uncontrolled hypertension; No New York Heart Association class III
             or IV disease

          -  Other: HIV negative; Not pregnant or nursing; Negative pregnancy test; Fertile
             patients must use effective contraception; No active autoimmune disease; No active
             infection requiring parenteral antibiotics; No uncontrolled diabetes mellitus; No
             other prior malignancy within the past 5 years except skin cancer or stage 0-II
             cervical cancer; No significant psychiatric disorders
Clinical trial NCT00296387 (phase 3, status: completed)
Conditions: acute coronary syndrome
ICD codes: I24.0
Drugs: rosuvastatin, atorvastatin
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Hospital admission for ACS with chest pain or discomfort occurring during rest or with
             minimal exertion,

          -  Percutaneous coronary intervention (PCI) planned,

          -  Evidence of coronary artery disease

        Exclusion Criteria:

          -  Hypersensitivity to statins

          -  Any cholesterol lowering medication taken within 1 month prior V1

          -  Sustained ST-segment elevation on ECG
Clinical trial NCT01070784 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: symbicort turbuhaler (budesonide/formoterol), drug: any available copd treatment; investigator to decide
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  A current clinical diagnosis of COPD according to the guidelines (GOLD, JPS)

          -  Documented COPD symptoms for more than 2 years

          -  Pre-bronchodilator FEV1≦50% of predicted normal value, and post-bronchodilator
             FEV1/FVC<70%

        Exclusion Criteria:

          -  History and/or current clinical diagnosis of asthma and atopic diseases such as
             allergic rhinitis

          -  Subjects with significant or unstable ischemic heart disease, arrhythmia,
             cardiomyopathy, heart failure, uncontrolled hypertension as defined by the
             investigator, or any other relevant cardiovascular disorder as judged by the
             investigator

          -  COPD exacerbation during the run-in period or within 4 weeks prior to registration,
             requiring hospitalization and/or treatment with systemic steroids.
Clinical trial NCT00376792 (phase 3, status: unknown status)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate meeting one of the following
             criteria after undergoing radical prostatectomy:

               -  pT2 with Gleason score 4+3 or 8-10 and positive margins in the radical
                  prostatectomy specimen

               -  Any pT3a tumor with Gleason score ≥ 4+3

               -  pT3b tumor with Gleason score ≥ 7

          -  Negative lymph nodes at histological examination (N0)

          -  Patients with a preoperative prostate-specific antigen (PSA) ≥ 10.0 ng/mL should have
             undergone a lymph node dissection

          -  Postoperative PSA must be < 0.5 ng/mL

          -  Considered at high risk for recurrent disease

          -  No metastatic (M0) disease

               -  Negative bone scan

        PATIENT CHARACTERISTICS:

          -  WHO/ECOG performance status 0-1

          -  Hemoglobin ≥ 11.0 g/dL

          -  Neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 150,000/mm³

          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)

          -  Bilirubin normal

          -  AST and ALT ≤ 1.5 times ULN

          -  Alkaline phosphatase < 1.5 times ULN

          -  No active untreated infectious disease (e.g., tuberculosis or methicillin-resistant
             Staphylococcus aureus)

          -  No active gastric ulcer

          -  No known hypersensitivity to polysorbate 80

          -  No symptomatic peripheral neuropathy ≥ grade 2

          -  No myocardial infarction within the past 6 months

          -  No other unstable cardiovascular disease within the past 6 months

          -  No other serious illness or medical condition

          -  No altered psychological or physical state that would preclude study compliance

          -  No other malignancy within the past 5 years except basal cell or squamous cell skin
             cancer

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior hormonal therapy (e.g., luteinizing hormone-releasing hormone analogues
             and/or antiandrogens) affecting prostate cancer cells

          -  No prior radiotherapy to the pelvis

          -  No prior chemotherapy

          -  More than 6 months since prior systemic corticosteroids

          -  No other concurrent anticancer therapy or investigational drugs
Clinical trial NCT00527514 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: amlodipine, olmesartan medoxomil plus amlodipine
SMILES: COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females greater than or equal to 18 years of age

          -  Patients with a mean seated systolic blood pressure (MSSBP) greater than or equal to
             140 mm Hg but less than or equal to 199 mm Hg or a mean seated diastolic blood
             pressure (MSDBP) greater than or equal to 90 mm Hg and less than or equal to 109 mm
             Hg, following a period of taking only placebo

          -  Patients with a mean daytime (8AM-4PM) systolic blood pressure greater than or equal
             to 135 mm Hg and less than or equal to 199 mm Hg and a mean daytime diastolic blood
             pressure less than or equal to 109 mm Hg as measured by an ambulatory blood pressure
             monitoring device (ABPM), after a period of taking only placebo

          -  If female, must have negative serum pregnancy test at screening and be either
             post-menopausal (greater than or equal to 1 year), had a hysterectomy or tubal
             ligation at least 6 months before consent or if of childbearing potential, must
             practice approved measures of birth control throughout study

        Exclusion Criteria:

          -  History of stroke or transient ischemic attack (TIA) within the last one year

          -  History of myocardial infarction, coronary angioplasty, coronary artery bypass graft,
             or heart failure within the past 6 months

          -  Patients with secondary hypertension of any etiology, such as renal disease,
             pheochromocytoma, or Cushing's syndrome

          -  Type I diabetes. Patients with Type II diabetes on stable treatment, with fasting
             glucose <160 mg/dl may enroll

          -  Patients with hemodynamically significant cardiac valvular disease

          -  Patients with clinically significant cardiac conduction defects, including second or
             third degree AV block, left bundle branch block, sick sinus syndrome, atrial
             fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring
             medication